EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:YMAB

Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

$4.34
+0.16 (+3.83%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.18
$4.43
50-Day Range
$3.00
$15.17
52-Week Range
$2.94
$20.48
Volume
268,106 shs
Average Volume
563,865 shs
Market Capitalization
$189.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
257.1% Upside
$15.50 Price Target
Short Interest
Healthy
4.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.21mentions of Y-mAbs Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$5,879 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.67) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.94 out of 5 stars

Medical Sector

42nd out of 1,038 stocks

Pharmaceutical Preparations Industry

17th out of 510 stocks

YMAB stock logo

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

Where Y-mAbs Therapeutics Stands With Analysts
YMAB Y-mAbs Therapeutics, Inc.
Y-mAbs Announces Pivotal Data for Omburtamab
Y Mabs Therapeutics
Y-mAbs Therapeutics, Inc. (YMAB)
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings
11/07/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+257.1%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-55,280,000.00
Net Margins
-307.75%
Pretax Margin
-307.75%

Debt

Sales & Book Value

Annual Sales
$34.90 million
Book Value
$4.13 per share

Miscellaneous

Free Float
34,668,000
Market Cap
$189.52 million
Optionable
Not Optionable
Beta
0.74

Key Executives

  • Mr. Thomas Gad (Age 52)
    Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director
    Comp: $772.34k
  • Mr. Bo Kruse (Age 50)
    Exec. VP, Sec., Treasurer & CFO
    Comp: $638.84k
  • Dr. Steen Lisby M.D. (Age 58)
    M.Sc., Sr. VP & Chief Scientific Officer
    Comp: $393.99k
  • Dr. Vignesh Rajah M.B.A. (Age 57)
    MBBS, Sr. VP & Chief Medical Officer
    Comp: $406.27k
  • Mr. Joris Wiel Jan Wilms (Age 48)
    Sr. VP & COO
  • Dr. Torben Lund-Hansen M.Sc. (Age 71)
    Ph.D., Sr. VP & Head of Technical Operations
  • Ms. Sue Smith (Age 51)
    Sr. VP & Chief Commercial Officer













YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price forecast for 2023?

8 equities research analysts have issued 1-year price targets for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $6.00 to $27.00. On average, they anticipate the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 259.6% from the stock's current price.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2022?

Y-mAbs Therapeutics' stock was trading at $16.21 at the beginning of 2022. Since then, YMAB stock has decreased by 73.4% and is now trading at $4.31.
View the best growth stocks for 2022 here
.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,470,000 shares, a drop of 52.3% from the October 31st total of 3,080,000 shares. Based on an average daily trading volume, of 601,800 shares, the days-to-cover ratio is currently 2.4 days. Currently, 4.2% of the company's stock are sold short.
View Y-mAbs Therapeutics' Short Interest
.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our YMAB earnings forecast
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its quarterly earnings results on Monday, November, 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.12. The business earned $12.54 million during the quarter, compared to analyst estimates of $11.69 million. Y-mAbs Therapeutics had a negative net margin of 307.75% and a negative trailing twelve-month return on equity of 92.65%.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $51.75 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.63%), Alliancebernstein L.P. (4.92%), Vanguard Group Inc. (4.40%), State Street Corp (4.39%), Dimensional Fund Advisors LP (0.30%) and Renaissance Technologies LLC (0.29%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $4.31.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $188.22 million and generates $34.90 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

The company employs 148 workers across the globe.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 11/29/2022 by MarketBeat.com Staff